newsfilter
← Latest News
GlobeNewswire·

Outlook Therapeutics® to Present at the H.C. Wainwright 24th Annual Global Investment Conference

ISELIN, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indicati